References
- Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non small cell lung cancer. Nature 2007;448:561-6
- Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non small cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;10:4247-53
- Reck M, Popat S, Reinmuth N, et al. Metastatic non small cell lung cancer (NSCLC): ESMO Clinical PracticeGuidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25:iii27-39
- Rothenstein JM, Letarte N. Managing treatment-related adverse events associated with Alk inhibitors. Curr Oncol 2014;21:19-26
- Girard N, Audigier-Valette C, Cortot AB, et al. ALK-rearranged non small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice? Expert Rev Anticancer Ther 2015;15:225-33
- Dikopf A, Wood K, Salgia R. A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients. Expert Opin Drug Saf 2015;14:485-93
- Ou SH, Tong WP, Azada M, et al. Heart rate decrease during crizotinib treatment and potential correlation to clinical response. Cancer 2013;119(11):1969-75
- U.S. Food and Drug Administration (FDA) drug safety communication: new information regarding QT prolongation with ondansetron. Available from: www.fda.gov/Drugs/DrugSafety/ucm310190.htm [Last accessed 15 September 2011]
- Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther 2010;31:11-19
- European Medicines Agency recommends changes to the use of metoclopramide. Available from: www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/07/news_detail_001854.jsp&mid=WC0b01ac058004d5c1 [Last accessed 26 July 2013]
- Rumore MM, Lee SE, Wang S, et al. Metoclopramide-induced cardiac arrest. Clin Pract 2011;1(4):e83
- Doherty KR, Wappel RL, Talbert DR, et al. Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol 2013;272:245-55
- Fitton A, Wiseman L. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996;51:460-82
- Xalkori (Pfizer Inc.) prescribing information [package insert]. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2011/202570s000lbl.pdf [Last accessed 02 2013]